Coya Q2 net loss $2.9M; FDA demands more data before COYA 302 ALS Phase 2

Coya Therapeutics, Inc.

2024-Q2 EPS reported -$0.54 revenue$3,552,109

Net loss $2.9M vs $3.1M YoY; collaboration rev $3.4M from Dr. Reddy's.
Cash $36.6M at June 30, 2024.
FDA requires additional non-clinical data before Phase 2 of COYA 302 in ALS; Coya plans to discuss in Q4 2024.
Received $5M strategic investment from ADDF for COYA 302 in FTD.
R&D expenses $4.6M (up from $1.1M) driven by preclinical costs for COYA 302.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.